Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRG50635 in healthy volunteers
NCT06286475Phase 1Completed
- Sponsor
- Verge Genomics
- Start
- Feb 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of VRG50635 (6 arms), sponsored by Verge Genomics. Primary endpoints: Adverse Events at 30 days, Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity at 16 days and 6 more. Started Feb 2024; status: completed.
02
Drugs
VRG50635
Beyond the preview
Go deeper on NCT06286475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06286475.